Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: quinolone antibacterials - Procter & Gamble

Drug Profile

Research programme: quinolone antibacterials - Procter & Gamble

Alternative Names: (3S)-Amino-(4R)-ethylpiperidinyl quinolones research programme - Procter & Gamble; 5,6-Bridged dioxinoquinolones research programme - Procter & Gamble; Non-fluorinated quinolones research programme - Procter & Gamble; PGE 836779; Quinolone antibacterials research programme - Procter & Gamble

Latest Information Update: 01 Dec 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Class Quinolones
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 06 Jan 2005 TaiGen Biotechnology entered a strategic alliance with Procter & Gamble for further development and commercialisation of an unspecified, non-fluorinated quinolone invented by Procter & Gamble. TaiGen has development and commercialisation rights in China, Taiwan, Korea and the ASEAN countries
  • 07 Jan 2004 A preclinical study has been added to the Bacterial Infections antimicrobial activity section
  • 05 Sep 2003 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top